Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2793)	6/29/2010 6:10:50 PM
From: mlkr	Read Replies (1) \| Respond to of 3722

APPY 093 now! cause of delay: AspenBio Tumbles On Expected Delay In FDA Filing Date : 06/07/2010 @ 9:39AM Source : Dow Jones News Stock : AspenBio Pharma Inc. (APPY) Quote : 0.97 0.02 (2.11%) @ 3:50PM noad AspenBio Tumbles On Expected Delay In FDA Filing Aspenbio Pharma (MM) (NASDAQ:APPY) Historical Stock Chart 1 Month : May 2010 to June 2010 Click Here for more Aspenbio Pharma (MM) Charts. DOW JONES NEWSWIRES AspenBio Pharma Inc. (APPY) said additional data analysis following a recent clinical trial will likely result in a delayed application for Food and Drug Administration clearance of its test for acute appendicitis. Shares slumped 42% to $1.95 in recent pre-market trading. Through Friday's close the stock has nearly doubled. The pharmaceutical start-up company had expected to submit its 510(k) application by late this month for the blood-based test, known as AppyScore. However, additional analysis is needed because of "unexplained variability in results from site to site" in the initial draft of the report.